| Document |
Document Title |
|
JP4946869B2 |
|
|
JP4928937B2 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metas...
|
|
JP4903922B2 |
Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic ...
|
|
JP2012056846A |
To provide a method of producing an amide or a lactam according to the Beckmann rearrangement of an oxime compound using a highly active catalyst system prepared by making use of inexpensive hydrogen chloride as a catalyst, capable of pr...
|
|
JP4885067B2 |
The present invention relates to compounds of the formulaQ is selected from the group consisting ofG is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo,W is O or NR15;X is O ...
|
|
JP4865708B2 |
The invention concerns a method for purifying cyclic lactams containing 6 to 12 carbon atoms and containing chlorolactams as impurities, by hydrogenation reaction in the presence of a metal catalyst, a solvent and a compound having a rad...
|
|
JP4869077B2 |
The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer (formula (I) and (IV). The present invention provides ...
|
|
JP2012500013A |
The present invention relates to a combination of cell lines as well as a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor anti-tumor agent. Also a method for determining the...
|
|
JP4773969B2 |
Compounds of formula I wherein n, m, p, q. Y, R 1 R 2 , R 3 , R 4 , R 6 , and R 6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
|
|
JP2011168612A |
To provide a method for economically, selectively and efficiently reducing the content of amine existing in N-substituted lactams as an impurity.The method for reducing the amine content of amine-contaminated N-substituted lactams compri...
|
|
JP4760917B2 |
|
|
JP4719671B2 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metas...
|
|
JP4717003B2 |
Compounds having a structure according to formula Iwherein the groups R<1 >and R<4 >are as defined in the specification, are useful as anti-proliferative agents.
|
|
JP2011105766A |
To provide pharmaceutical compositions and a method for treating mammary tumor metastasis in a subject.The invention provides pharmaceutical compositions comprising a therapeutically effective amount of compounds of general formula (I), ...
|
|
JP2011515086T |
Nucleotide sequence;, or (d) arrangement number 1 and at least 85% of arrangement identity (preferably) in which nucleotide sequence; or (c) arrangement number 1 which is a phase assistant object of nucleotide sequence; or (b) arrangemen...
|
|
JP2011088883A |
To provide a method for producing an amide or a lactam by which the amide or the lactam can be formed in high conversion and high yield without forming a large amount of byproducts such as ammonium sulfate in the method for producing the...
|
|
JP4639781B2 |
|
|
JP2011016765A |
To efficiently separate a sulfur component from an organic solution containing the sulfur component and especially in a production of lactam by subjecting a cycloalkanone oxime to a Beckmann rearrangement using a sulfur compound such as ...
|
|
JP2010229042A |
To provide a method for producing laurolactam by which the laurolactam is formed in high conversion and high yield without causing precipitation of a catalyst, a catalyst decomposition product or the like in the method for producing the ...
|
|
JP4562370B2 |
|
|
JP2010222272A |
To provide a method for producing laurolactam from cyclododecanone oxime by a Beckmann rearrangement reaction using a catalyst in a nonpolar solvent, where deposition of the catalyst, a catalyst decomposition product or the like is not c...
|
|
JP4525418B2 |
To provide a solid acid catalyst useful for acid catalytic reaction, that is, to provide a simple preparation method of a solid acid catalyst for producing a lactam compound at a high yield in a moderate reaction condition at the time of...
|
|
JP4491335B2 |
|
|
JP2010520190A |
According to the invention there are provided derivatives of a C21-deoxy ansamycin or salt thereof which contain a 1-hydroxyphenyl moiety bearing at position 3 an aminocarboxy substituent, in which position 5 and the aminocarboxy substit...
|
|
JP2010516282A |
Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism Streptomyces hygroscopicus var. geldanus NRRL 3602, wherein the gene cluster encoding enzym...
|
|
JP2010512397A |
Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are...
|
|
JP4443043B2 |
The present application is directed to several newly prepared semi-synthetic ecteinascidin (Et) species, designated herein as Boc-Et 729, Et 875, and Et 1560. The physical properties of these compounds, their preparation and bioactivitie...
|
|
JP2010509306A |
The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases depend...
|
|
JP2010509307A |
The present invention relates to macbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases depende...
|
|
JP2010505860A |
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This...
|
|
JP4415580B2 |
|
|
JP4415576B2 |
|
|
JP2009275005A |
To provide an industrially advantageous production method by which laurolactam can readily be produced in high yield in the production of the laurolactam by Beckmann rearrangement of cyclododecanone oxime.The method for producing the lau...
|
|
JP2009269908A |
To provide a production method of laurolactam by means of the Beckmann rearrangement reaction of cyclododecanone oxime, wherein an industrially advantageous production method of easily producing the laurolactam at a high yield is provide...
|
|
JP2009539880A |
Substituted phenyl acetic acid compounds of formula (I), pharmaceutical compositions, methods for their preparation and methods are provided that are useful in the treatment and prevention of disorders or conditions responsive to DP 2 re...
|
|
JP2009256388A |
To provide a new hybrid drug for cancer treatment and for releasing the drug by setting a target on cancer cells.Provided is a hybrid drug for cancer treatment, having a targeting moiety specifically bonding with proteins, receptors and ...
|
|
JP4358851B2 |
The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is (S)-8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-(4-...
|
|
JP2009249336A |
To provide a simple and commercailly advantageous method for producing laurolactam by conducting a Beckmann rearrangement reaction of cyclododecanonoxime.The method for producing laurolactam comprises conducting a Beckmann rearrangement ...
|
|
JP2009536934A |
The present invention relates to 17-oxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases d...
|
|
JP2009536181A |
The present invention relates to 18,21-didesoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, di...
|
|
JP2009221142A |
To provide an industrially advantageous manufacturing method that realizes simple and high-yielding manufacture of laurolactam in the manufacture of laurolactam by a Beckmann rearrangement reaction of cyclododecanone oxime.The manufactur...
|
|
JP2009191000A |
To establish the total synthesis method of cytotrienin A, to provide an intermediate compound for synthesizing an ansamycin-based antibiotic comprising the cytotrienin A, to provide a method for producing the intermediate compound, and t...
|
|
JP4316203B2 |
The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is (S)-8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-(4-...
|
|
JP2009173614A |
To provide a method for producing laurolactam which can be suitably used for eliminating much energy loss by the Beckmann rearrangement of cyclododecanone oxime using a small amount of catalyst.By using catalytic amounts of phosphorus pe...
|
|
JP2009167112A |
To provide a method for producing laurolactam solving a problem of a large amount of sulfonic acid loss or a large energy loss by producing the laurolactam with the Beckmann rearrangement of cyclododecanone oxime by using a catalytic amo...
|
|
JP2009167111A |
To provide a method for producing laurolactam solving a problem of a large amount of sulfonic acid loss or a large energy loss by producing the laurolactam with the Beckmann rearrangement of cyclododecanone oxime by using a catalytic amo...
|
|
JP4297115B2 |
|
|
JP2009521423A |
The present invention relates to 21-deoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases...
|
|
JP2009517386A |
Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).
|
|
JP2009513498A |
This invention describes a process for the production of C1-C15-fragments of epothilones and derivatives thereof, in which a C1-C6-fragment is linked with a C7-C12-fragment to a C1-C12-fragment, and the latter then is reacted with a C13-...
|
